- Allergan Ligand Retinoid Therapeutics posted a net loss of $4.5 million or $1.39 per share in the third quarter of 1995. For the nine months ended September 30, 1995, the net loss was $12.5 million. No revenues were recorded. During the third quarter, ALRT announced early activity in cutaneous Kaposi's sarcoma with topical ALRT-1057, indicating that the agent induced a partial or complete response in one or more treated lesions in 65% of 20 patients with AIDS-related KS.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze